Palette Life Sciences Announces Completion of $30 Million Equity Financing and Expansion of the Board of Directors
Summary
-Funds will be used for expansion of commercial US footprint and acceleration of clinical development of Barrigel®- SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, a Swedish domiciled, fully integrated global life sciences company dedicated to improving patient outcomes, announced today that the company has completed a $30 million equity financing during the spring and also expanded its Board of Directors by five members. New members of the Palette Life Sciences Board of Directors include the following: • Dave R. Amerson (Chairman) is a former Chief Executive Officer of NeoTract and former president of the Teleflex Urology franchise. Mr. Aguiar has been involved with several successful health care investments and in addition to Palette Life Sciences, he currently sits on the board of OssDsign AB. Palette Life Sciences’ products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, Dallas, Texas, and Sydney, Australia.